This announcement is a separate document:
サンバイオ：日本におけるSB623慢性外傷性脳損傷（TBI）プログラムの製造および販売承認の状況に関するさらなる最新情報
SanBio: Further updated information regarding the manufacturing and sales approval status of the SB623 chronic traumatic brain injury (TBI) program in Japan.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.